Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
about
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseComparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysisHighlights for ESMO 40: celebration review for lifetime achievement awardsRandomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysisEffect of renal function on pemetrexed-induced haematotoxicityPhase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancerFunctional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.DNA topoisomerase I drugs and radiotherapy for lung cancer.Combination therapy versus single agent chemotherapy in non-small cell lung cancer.Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles.Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.Therapeutic strategy for treatment of metastatic non-small cell lung cancer.Polymeric micellar delivery systems in oncology.Combined small cell lung carcinoma and giant cell carcinoma: a case report.Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials.Treatment of non-small cell lung cancer (NSCLC).Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum.Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.Magnetic-Fe/Fe(3)O(4)-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages.7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in-vivo evaluation.Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan.Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine.Estimation of the average causal effect among subgroups defined by post-treatment variables.
P2860
Q24200518-1A0EB0EA-9545-4D7B-BADB-1B7903FE20EFQ24243664-1529433A-7F89-45EF-BB6E-12174E7060A2Q26775554-15D5BC84-E671-44E6-9242-8CEF03CF90ABQ28075787-41FA3802-3018-4852-9832-D77F8BA4C4A6Q33358448-9291E5BE-E6B3-474D-9F7A-4379D96C9DB8Q33393268-2C770960-3B71-4E90-9096-9742EA4B4964Q33421419-B740AF3D-D44B-4922-8B15-074CF7E69AA5Q33432955-AB8F6A08-BA4B-4F06-82C1-5A5DE75D1E41Q35527148-13C63C5E-8037-477A-9C52-4D8A028D66A8Q35655672-C8166BFB-A6C6-401A-AF51-0B386B044F45Q36186315-48CD4DB0-4631-4915-A42D-69EA8E44CE08Q36222050-2DECC4EC-DA46-4D4A-AA53-0F95ED47C701Q36614907-74B5A439-648E-4D36-A391-4CEDD9A00784Q36615741-FBF3FD47-3B9E-4DAB-A941-0CE5088C8E8FQ36900219-03D4DE0E-7E94-4EFA-8316-BB09FEAA91C2Q37091425-49F3B204-C23E-435D-B4CE-DBB05C1EA929Q37310694-A794D3E3-6049-4EF4-AC96-B0F55D5B0016Q37319114-5ED0E5A7-FC04-46A3-AD48-1215837E34A6Q37733342-F21BE695-A153-4F52-9CE2-BC7C11407600Q37986608-35D73297-EB46-47FB-ACB0-37B2B2CE414BQ38150348-E0EBD96E-B855-4EA1-BF34-C179E0FD25BDQ40009120-22CE3D74-9EB5-48B1-9225-5C7458CA5CC5Q40184647-9330EED2-7810-4A3B-84EF-61ED7B327787Q40303807-3E84DE55-35E1-41A1-9AAA-161858DAD2DCQ42223084-A6E6B5B8-B725-46C6-AB39-F154EF8AE60AQ46401314-56C1CBC9-7CDB-4786-A7F4-3F23B7DA1EF5Q46441693-6D4C84BF-D4A4-4D47-91B8-459AC0361808Q48153064-23CEA96D-7F81-49E3-B5BC-7CE238D3120CQ53000551-F12D463E-BC4A-4920-BF42-A8D24DDAD193
P2860
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2003
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomised phase III trial of ...... ced non-small-cell lung cancer
@en
Randomised phase III trial of ...... ed non-small-cell lung cancer.
@nl
type
label
Randomised phase III trial of ...... ced non-small-cell lung cancer
@en
Randomised phase III trial of ...... ed non-small-cell lung cancer.
@nl
prefLabel
Randomised phase III trial of ...... ced non-small-cell lung cancer
@en
Randomised phase III trial of ...... ed non-small-cell lung cancer.
@nl
P2093
P2860
P356
P1476
Randomised phase III trial of ...... ced non-small-cell lung cancer
@en
P2093
CPT-11 Lung Cancer Study Group West
N Katakami
Y Ariyoshi
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600725
P407
P577
2003-02-01T00:00:00Z